Casdin Capital LLC Has $81.72 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Casdin Capital LLC lowered its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 24.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,175,000 shares of the company’s stock after selling 380,000 shares during the quarter. Structure Therapeutics comprises approximately 5.1% of Casdin Capital LLC’s investment portfolio, making the stock its 6th largest holding. Casdin Capital LLC owned about 1.94% of Structure Therapeutics worth $81,721,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Avoro Capital Advisors LLC increased its holdings in shares of Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares in the last quarter. BVF Inc. IL increased its holdings in shares of Structure Therapeutics by 8.6% during the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after acquiring an additional 275,105 shares in the last quarter. Morgan Stanley increased its holdings in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Structure Therapeutics by 477.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 7.2% during the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after acquiring an additional 106,389 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent analyst reports. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. HC Wainwright cut their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, June 11th. Canaccord Genuity Group initiated coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. Citizens Jmp cut their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Finally, BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Stock Up 4.9%

Shares of NASDAQ GPCR opened at $45.00 on Thursday. The business’s 50 day moving average price is $43.09 and its 200 day moving average price is $57.53. The firm has a market cap of $3.20 billion, a P/E ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.